{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:18:18Z","timestamp":1779909498863,"version":"3.53.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.yebeh.2020.107286","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T02:44:16Z","timestamp":1595299456000},"page":"107286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"111","author":[{"given":"Joshua M.","family":"DeMott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles W.","family":"Slocum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Peksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107286_bb0005","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2014report of the ILAE task force on classification of status epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107286_bb0010","doi-asserted-by":"crossref","first-page":"106720","DOI":"10.1016\/j.yebeh.2019.106720","article-title":"Epidemiology of status epilepticus in adults: apples, pears, and oranges \u2014 a critical review","volume":"103","author":"Leitinger","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107286_bb0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(06)69043-0","article-title":"Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study","volume":"368","author":"Chin","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107286_bb0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2020.107286_bb0025","doi-asserted-by":"crossref","first-page":"106675","DOI":"10.1016\/j.yebeh.2019.106675","article-title":"Management of status epilepticus in adults position paper of the Italian League Against Epilepsy","volume":"102","author":"Minicucci","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107286_bb0030","series-title":"Advanced paediatric life support: a practical approach to emergencies","author":"Advanced Life Support Group (ALSG)","year":"2016"},{"key":"10.1016\/j.yebeh.2020.107286_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2019.11.007","article-title":"Therapeutic effect of intravenous levetiracetam in status epilepticus: a meta-analysis and systematic review","volume":"74","author":"Chu","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107286_bb0040","doi-asserted-by":"crossref","first-page":"106466","DOI":"10.1016\/j.yebeh.2019.106466","article-title":"Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis","volume":"101","author":"Brigo","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107286_bb0045","doi-asserted-by":"crossref","first-page":"e2339","DOI":"10.1212\/WNL.0000000000007503","article-title":"Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus","volume":"92","author":"Sanchez Fernandez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107286_bb0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pediatrneurol.2008.01.001","article-title":"Treatment of refractory status epilepticus: literature review and a proposed protocol","volume":"38","author":"Abend","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2020.107286_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1059-1311(02)00338-2","article-title":"Adverse events associated with intravenous phenytoin in children: a prospective study","volume":"12","author":"Appleton","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107286_bb0060","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00415-015-7967-1","article-title":"Cardiovascular adverse effects of phenytoin","volume":"263","author":"Guldiken","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2020.107286_bb0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1756285608100460","article-title":"New treatment options in status epilepticus: a critical review on intravenous levetiracetam","volume":"2","author":"Trinka","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.yebeh.2020.107286_bb0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00207454.2013.866951","article-title":"The adverse effects profile of levetiracetam in epilepsy: a more detailed look","volume":"124","author":"Mbizvo","year":"2014","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.yebeh.2020.107286_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bcp.13400","article-title":"Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children","volume":"84","author":"van Dijkman","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2020.107286_bb0080","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","article-title":"Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial","volume":"393","author":"Dalziel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107286_bb0085","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","article-title":"Randomized trial of three anticonvulsant medications for status epilepticus","volume":"381","author":"Kapur","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2020.107286_bb0090","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","article-title":"Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial","volume":"393","author":"Lyttle","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107286_bb0095","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","article-title":"Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial","volume":"15","author":"Noureen","year":"2019","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2020.107286_bb0100","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.4103\/jfmpc.jfmpc_750_19","article-title":"Levetiracetam versus phenytoin in children with status epilepticus","volume":"8","author":"Wani","year":"2019","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.yebeh.2020.107286_bb0105","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2020.107286_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.yebeh.2020.107286_bb0115","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2020.107286_bb0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2020.107286_bb0125","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13643-017-0644-y","article-title":"Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study","volume":"6","author":"Bramer","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.yebeh.2020.107286_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eplepsyres.2015.04.013","article-title":"Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam\u2014pilot study","volume":"114","author":"Mundlamuri","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2020.107286_bb0135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jocn.2014.12.013","article-title":"Levetiracetam versus phenytoin in management of status epilepticus","volume":"22","author":"Chakravarthi","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2020.107286_bb0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.seizure.2017.05.001","article-title":"Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study","volume":"49","author":"Gujjar","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107286_bb0145","first-page":"237","article-title":"Randomized controlled trial of levetiracetam versus fosphenytoin for convulsive status epilepticus in children","volume":"5","author":"Senthilkumar","year":"2018"},{"key":"10.1016\/j.yebeh.2020.107286_bb0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MOP.0000000000000616","article-title":"An update in the initial management of paediatric status epilepticus","volume":"30","author":"Lawton","year":"2018","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.yebeh.2020.107286_bb0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40265-017-0859-1","article-title":"Pharmacotherapy for refractory and super-refractory status epilepticus in adults","volume":"78","author":"Holtkamp","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2020.107286_bb0160","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/00002018-200022060-00004","article-title":"Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs","volume":"22","author":"DeToledo","year":"2000","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2020.107286_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00003088-200342010-00002","article-title":"Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures","volume":"42","author":"Fischer","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.yebeh.2020.107286_bb0170","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.seizure.2019.10.006","article-title":"Medical management of status epilepticus: emergency room to intensive care unit","volume":"75","author":"Crawshaw","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107286_bb0175","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073808331351","article-title":"Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study","volume":"24","author":"Wheless","year":"2009","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107286_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12028-019-00708-5","article-title":"Safety and tolerability of rapid administration undiluted levetiracetam","volume":"30","author":"Morgan","year":"2020","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.yebeh.2020.107286_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yebeh.2017.03.018","article-title":"The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined?","volume":"71","author":"Redecker","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107286_bb0190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ana.25416","article-title":"Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE)","volume":"85","author":"Kellinghaus","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2020.107286_bb0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107286_bb0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1474-4422(15)00296-3","article-title":"Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial","volume":"15","author":"Navarro","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020304650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020304650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:34:19Z","timestamp":1761503659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020304650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":40,"alternative-id":["S1525505020304650"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107286","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107286"}}